The pharmaceutical company informed the stock exchanges in a filing that it has received marketing authorisation for Southeast Asia’s largest pharmaceutical market, Indonesia, for its anticoagulant ‘Enoxaparin’.
The pharmaceutical company informed the stock exchanges in a filing that it has received marketing authorisation for Southeast Asia’s largest pharmaceutical market, Indonesia, for its anticoagulant ‘Enoxaparin’.